Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401087 | 1.00 | MDM4 (0.60) | MDM4TP53KMT2ACASP3MDM2 | |
| SCHEMBL29400989 | 1.00 | MDM4 (0.60) | MDM4TP53KMT2ACASP3MDM2 | |
| SCHEMBL418101 | 1.00 | MDM4 (0.60) | MDM4TP53KMT2ACASP3MDM2 | |
| SCHEMBL15806915 | 1.00 | MDM4 (0.60) | MDM4TP53KMT2ACASP3MDM2 | |
| Hydrochloric Acid SCHEMBL23455559 | 0.99 | MDM4 (0.59) | MDM4TP53KMT2ACASP3MDM2 | |
| Hydrochloric Acid SCHEMBL16620346 | 0.99 | MDM4 (0.59) | MDM4TP53KMT2ACASP3MDM2 | |
| Hydrochloric Acid SCHEMBL31370422 | 0.99 | MDM4 (0.59) | MDM4TP53KMT2ACASP3MDM2 | |
| Trifluoroacetic Acid SCHEMBL4363454 | 0.94 | MDM4 (0.55) | MDM4TP53KMT2ACASP3MDM2 | |
| SCHEMBL29541007 | 0.90 | MDM4 (0.58) | MDM4TP53KMT2ACASP3MDM2 | |
| SCHEMBL16095190 | 0.90 | MDM4 (0.58) | MDM4TP53KMT2ACASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| WO-2025131101-A1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海多米瑞生物技术有限公司 | 2025-06-26 | — | — | WO | disclosed |
| CN-120192363-A | Polypeptide compound, pharmaceutical composition thereof and application thereof | 上海多米瑞生物技术有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4499667-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-02-05 | — | — | EP | disclosed |
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
| EP-0903353-B1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-11-25 | — | — | EP | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| EP-1761783-B1 | IDENTIFICATION OF COMPOUNDS MODIFYING A CELLULAR RESPONSE | 2CUREX APS (DK) | 2009-07-29 | — | — | EP | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | MDM4 672/4885TP53 75/4885KMT2A 3513/4885 |
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | MDM4 4298/4885TP53 4507/4885KMT2A 4800/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | MDM4 4298/4885TP53 4507/4885KMT2A 4800/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | MDM4 4298/4885TP53 4507/4885KMT2A 4800/4885 |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | MDM4 1323/4885TP53 3844/4885KMT2A 2907/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1128/4885TP53 158/4885KMT2A 2293/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | MDM4 1648/4885TP53 614/4885KMT2A 3083/4885 |
| US-20100173835-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | MDM4 4558/4885TP53 4757/4885KMT2A 2745/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | MDM4 4298/4885TP53 4507/4885KMT2A 4800/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | MDM4 4563/4885TP53 4218/4885KMT2A 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.